28.79USDMkt Cap: 1.71B USDP/E: —Last update: 2026-05-21
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-ty…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap1.71B USD
Enterprise Value1.01B USD
Revenue (TTM)66.05M USD
Gross Profit47.68M USD
Net Income (TTM)-412.78M USD
Revenue/Share1.133 USD
Last Price28.79 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees539
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS00847X1046
Valuation
P/E (Trailing)—
P/E (Forward)-6.26
PEG—
EV/EBITDA-2.15
EV/Revenue15.31
P/S25.92
P/B1.54
EPS (TTM)-7.26
EPS (Forward)-4.60
52W Range
27.7199% of range28.80
52W High28.80 USD
52W Low27.71 USD
Profitability
Gross Margin88.26%
Oper. Margin-530.34%
EBITDA Margin0.00%
Profit Margin-764.01%
ROE-34.60%
ROA-31.82%
Growth
Revenue Growth137.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-372.98M USD
CapEx (TTM)14.32M USD
FCF Margin-404.59%
FCF Yield-15.61%
Net Debt-701.29M USD
Net Debt/EBITDA1.49
Balance Sheet
Debt/Equity0.03
Current Ratio14.19
Quick Ratio12.80
Book Value/Sh18.69 USD
Cash/Share12.39 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.6 (Buy)
Target (Mean)41.13 USD
Target Range28.00 USD – 60.00 USD
# Analysts8
Ownership
Shares Out.59.47M
Float53.13M
Insiders1.09%
Institutions108.65%
Short Interest
Short Ratio4.8d
Short % Float11.85%
Short % Out.11.73%
Shares Short6.97M
Short (prev mo.)6.61M
Technical
SMA 5029.46 (-2.3%)
SMA 20032.49 (-11.4%)
Beta0.58
S&P 52W Chg28.31%
Avg Vol (30d)507.07K
Avg Vol (10d)677.45K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—